Compare McKesson Corporation (MCK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Veritone Inc — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Veritone Inc trades at $1.05 (market cap $97.60M). The key difference: McKesson Corporation is far larger — about 997.4× Veritone Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| MCK | VERI | |
|---|---|---|
Market Cap | $97.35B | $97.60M |
Sector | Health | Technology |
52-Week High | $995.69 | $8.39 |
52-Week Low | $659.01 | $1.02 |
Enterprise Value | $101.98B | $129.63M |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VERI trades at $1.05, up 2.94% on the day, but remains in a bearish technical trend. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, while revenue declined to $92.19 million. Multiple securities class action lawsuits, with a July 20, 2026 deadline, highlight significant legal and reputational risks stemming from alleged improper revenue accounting.
The outlook is highly speculative given severe profitability challenges and ongoing litigation. Analyst consensus is split between Buy and Hold, but fundamental weaknesses and legal overhangs present substantial downside risk. Investment suitability is limited to risk-tolerant investors monitoring resolution of legal issues and a path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
